Imneskibart - Aulos Bioscience
Alternative Names: AU-007; BD-8; BDG8Latest Information Update: 20 Nov 2025
At a glance
- Originator Biolojic Design
- Developer Aulos Bioscience; Biolojic Design
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin-2 receptor alpha subunit antagonists; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 07 Nov 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Aulos Bioscience
- 29 Apr 2025 Interim adverse events, pharmacodynamics and efficacy data from a phase-I/II trial in Solid tumours released by Aulos Bioscience
- 25 Apr 2025 Updated efficacy and adverse event data from a phase I/II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)